Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Zymeworks Inc. | Chief Scientific Officer | Common Shares | 36.4K | $164K | $4.51 | Jan 7, 2022 | Direct |
BRAINSTORM CELL THERAPEUTICS INC. | Director | Common Stock | 26K | $46.1K | $1.77 | Feb 1, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
BCLI | BRAINSTORM CELL THERAPEUTICS INC. | Feb 1, 2022 | 1 | $0 | 4 | Feb 3, 2022 | Director |
ZYME | Zymeworks Inc. | Jan 7, 2022 | 1 | $1.03K | 4 | Jan 7, 2022 | Chief Scientific Officer |
BCLI | BRAINSTORM CELL THERAPEUTICS INC. | Dec 15, 2021 | 1 | $0 | 4 | Dec 17, 2021 | Director |
BCLI | BRAINSTORM CELL THERAPEUTICS INC. | Dec 10, 2021 | 2 | $0 | 4 | Dec 10, 2021 | Director |
ZYME | Zymeworks Inc. | Aug 31, 2021 | 2 | $73.5K | 4 | Sep 2, 2021 | Chief Scientific Officer |
ZYME | Zymeworks Inc. | Jul 6, 2021 | 1 | $13.4K | 4 | Jul 8, 2021 | Chief Scientific Officer |